Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Paraproteinemias 1Neoplasms, Plasma Cell 1Natural Killer/T-cell Lymphoma 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Immunoproliferative Disorders 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × isatuximab × Lymphoid × Clear all
NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Indapta Therapeutics, INC.

Phase 1/2 Recruiting
128 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡